Sanofi (NASDAQ:SNY) Rating Increased to Strong-Buy at StockNews.com

StockNews.com upgraded shares of Sanofi (NASDAQ:SNY) from a buy rating to a strong-buy rating in a research note published on Friday.

Separately, Argus raised their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a buy rating in a research note on Friday. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of Moderate Buy and a consensus price target of $57.50.

Sanofi Trading Down 0.6 %

Sanofi stock opened at $52.09 on Friday. The stock has a 50-day simple moving average of $49.29 and a 200 day simple moving average of $48.66. The stock has a market capitalization of $131.93 billion, a P/E ratio of 26.18, a PEG ratio of 1.63 and a beta of 0.59. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a 52 week low of $42.63 and a 52 week high of $55.72.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The business had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. During the same period in the previous year, the firm earned $0.95 EPS. The firm’s revenue was up 7.8% compared to the same quarter last year. Analysts expect that Sanofi will post 4.14 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. POM Investment Strategies LLC acquired a new position in shares of Sanofi in the second quarter valued at about $25,000. Venturi Wealth Management LLC grew its position in shares of Sanofi by 163.5% during the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after purchasing an additional 332 shares in the last quarter. Frazier Financial Advisors LLC acquired a new position in shares of Sanofi during the 4th quarter worth approximately $28,000. Larson Financial Group LLC raised its position in shares of Sanofi by 480.8% in the first quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after buying an additional 500 shares in the last quarter. Finally, Register Financial Advisors LLC acquired a new stake in shares of Sanofi in the first quarter valued at approximately $29,000. Institutional investors own 10.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.